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Abstract
Purpose To develop and validate a new disease-specific
quality of life measure in hyperhidrosis for use in both
routine clinical practice and clinical research.
Methods Interviews and focus group discussions with
hyperhidrosis patients, reported elsewhere, provided the
content for the measure validated in this study (n = 71). A
panel of dermatologists (n = 5) and patients (n = 7) car-
ried out content validation. Further, item reduction and the
initial construct validation were carried out in a cross-
sectional study (n = 595), using the unidimensional Rasch
analysis and exploratory factor analysis. Subsequently, the
construct validity, reliability and responsiveness of the
revised measure were assessed in a longitudinal study
(n = 260). Data collection for the item reduction and the
final validation phases was entirely carried out online.
Results The expert panels judged the HidroQoL as content
valid. Rasch analysis supported the revision of response
options from five to three. Following removal of misfitting
items, a set of 15 items showed optimal fit to the model (chi-
squared statistic = 159.64, p = 0.07). Three additional
items were retained on consideration of their importance to
patients, resulting in an 18-item instrument. The items were
grouped into two subscales, daily life activities and psy-
chosocial life domains, based on results of the factor ana-
lysis. In subsequent construct validation, the HidroQoL
correlated with the DLQI (rs = 0.6, p \ 0.01). Reliability
was high (internal consistency, Cronbach’s alpha: overall
scale = 0.9; test–retest reliability, Intra-class correla-
tion = 0.9). The HidroQoL scores were sensitive to change
in patients’ disease severity (score change from baseline to
follow-up after 15–35 days, Cohen’s ES = 0.47).
Conclusion This study has provided the initial evidence
supporting measurement properties and the use of the Hid-
roQoL instrument in both routine clinical practice and in
research, for assessing quality of life impacts in hyperhidrosis.
Keywords Patient-reported outcome measure  Quality
of life  Hyperhidrosis  Excessive sweating  Hyperhidrosis
Quality of Life Index  HidroQoL
Introduction
Hyperhidrosis, a skin disorder characterised by excessive
sweating without aetiology [1], results in substantial
impairment in patients’ daily life [2, 3]. Assessing such
impacts is key to confirming the diagnosis and establishing
the severity of the condition [4], given the difficulty of
quantifying and interpreting laboratory-based measure-
ments of disease severity in hyperhidrosis [5]. The mea-
surement of health-related quality of life (HRQoL),
therefore, is central to the clinical management of hyper-
hidrosis, suggesting the need for measures that are appro-
priate and fit for purpose. Psychometric attributes such as
validity (that an instrument indeed measures what it
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purports to measure [6]) and reliability (that scales are
internally consistent and yield reproducible scores) are an
important consideration in determining this. For instru-
ments used longitudinally, responsiveness, a measure’s
ability to detect small but clinically important change over
time [7], is also required. Ultimately, the usefulness of a
measure depends on the interpretability of its scores, the
ability to decipher clinically relevant meaning from the
scores [8].
The measures currently in use for assessing HRQoL in
hyperhidrosis were reviewed. Generic HRQoL measures
such as the SF-36 or the NHP consist of items irrelevant for
hyperhidrosis patients, while omitting some key issues [9].
This also applies to dermatology-specific measures (Skin-
dex, Dermatology Life Quality Index-DLQI, and Patient
Benefit Index) albeit to a lesser degree. Among the disease-
specific measures, including those where patient involve-
ment in the development process (concept elicitation) was
mentioned (Hyperhidrosis Impact Questionnaire—HHIQ;
Hyperhidrosis Questionnaire—HQ; Amir’s Quality of Life
Instrument), it was not possible to establish that the content
was appropriate and had the right emphasis for patients
with hyperhidrosis. It was also unclear whether the expe-
rience and views of hyperhidrosis patients in Israel (for the
‘Amir’s instrument) and Korea (for the HQ) would be
similar/relevant/comparable with UK or US patients.
Only one out of five disease-specific measures (HHIQ)
provided information on all basic psychometric properties
(reproducibility, construct/convergence validity/external
validity and responsiveness). Among the other measures, the
assessment or reporting of psychometric properties such as
reliability and construct validity was often poor [10]. None
of the disease-specific instruments has been evaluated based
on modern test theory, for example, differential item func-
tioning for key demographic factors has not been assessed.
Clinical appropriateness was largely overlooked. Even the
most promising measure, the HHIQ, has not been adapted
for use in routine clinical practice [11].
It is considered to be a good practice to build upon
existing measures (e.g. improved or shortened) instead of
developing a new measure to overcome the inadequacies of
the existing ones. In the first instance, the onus of such
approach should be on the original developers. Other
researchers making such an attempt would be faced with
the difficulty of not having access to the original data,
opposition of the original developers being protective
about their measure and attitude of the scientific journals
towards publishing such work. Such instrument modifica-
tion work stands to be considered a compromise to starting
on a clean slate without any background noise or bias that
could be inherent in the existing measures.
There is therefore an urgent need for a fully validated
pragmatic instrument for evaluating hyperhidrosis-specific
QoL, for use in both routine clinical practice and clinical
research. Such an instrument could enhance the diagnosis
and management of the condition. Also, a practical mea-
sure may make it easy to integrate HRQoL information into
discussions between clinicians and patients during con-
sultation [12]. The current study therefore describes the
development and validation of such an instrument, the
Hyperhidrosis Quality of Life Index (HidroQoL).
Development of the new instrument
The new instrument was developed based on interviews
and focus groups carried out to investigate the impacts of
hyperhidrosis on patients’ lives (n = 71) [13]. A manu-
script containing the results of the qualitative study is
currently undergoing submission. The themes and subthe-
mes identified from the study were used in developing the
conceptual framework and items of the new measure, based
on the following criteria: all issues with prevalence of
C5 % were included; item phrasing was based on the
language used by patients and at the reading level of a
12-year old and item stems were suitable for and consistent
with the response categories [14]. The resultant prototype
instrument contained 47 items scored on a 6 point scale
(No not at all, A little, Somewhat, Quite a bit, Very much
and Not relevant).
Methods
Ethical approval and patient consent
This study was approved by the ethics committee of the
University Hospital of Greifswald, Germany. As the data
collection was carried out online and was based in Gre-
ifswald/Germany, the local ethics committee (S Wales)
waived the need for ethical clearance in Wales/UK. All
participants gave written informed consent prior to their
participation in the study.
Patient population
The patients participating in this study (Steps 2 and 3) were
recruited through online social networking communities
for hyperhidrosis, mostly drawn from the International
Hyperhidrosis Society and the UK Hyperhidrosis Support
Group. Both groups maintain an internet portal, a Facebook
group/page and circulate an e-mail-based newsletter peri-
odically, for sharing information among members. An
advert about the study containing contact details of the
research team and a link to the study website was posted
across all online communication channels of the groups.
Patients who contacted the research team, fulfilling the
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inclusion/exclusion criteria and willing to give written
informed consent were subsequently recruited into the
study. Study participants had self-reported hyperhidrosis,
were aged 18 years or above, had a Hyperhidrosis Disease
Severity Score (HDSS) of at least 2 (tolerable sweating but
sometimes interferes with daily activities), and onset of
hyperhidrosis at or before early adult years. There were no
incentives offered to patients for their participation in the
study.
Study design
A mixed methods design with multiple steps was followed
in this study. In Step 1, content validation was assessed by
two expert panels (patients, n = 7 and clinicians, n = 5),
quantitatively using a questionnaire (content validation
questionnaire) administered by e-mail and through an
expert panel discussion. Recommendations provided by
panel members on any aspects of the HidroQoL were
documented. In Step 2, initial construct validation and item
reduction were carried out based on patient responses to the
developmental instrument in a cross-sectional study
(cohort 1, n = 595). In Step 3, further validation was
carried out on the new instrument (final version) to estab-
lish reliability, construct validity and responsiveness. This
involved implementing a longitudinal study, with patients
assessed on three occasions using the final version of the
new instrument: at baseline, after 7 and after 21 days
(cohort 2, n = 260). Reliability was tested by assessing
internal consistency (using the baseline assessment) and
test–retest reliability (assessed by examining reproducibil-
ity of scores from baseline to first follow-up in those with a
stable condition). Construct validity of the HidroQoL was
tested by evaluating its relationship with other measures of
disease activity and disease impact in hyperhidrosis.
Responsiveness was tested in a longitudinal study, by
assessing change in scores from baseline to second follow-
up after 15–35 days.
Measures
In the content validation questionnaire, used in step 1, each
item was rated for language clarity, completeness, rele-
vance and appropriateness of response scaling, according
to a 4 point Likert scale (1 = strongly disagree, 2 = dis-
agree, 3 = agree, 4 = strongly agree). During Steps 2 and
3, patients completed the following instruments, in addition
to the new measure under development: the Hyperhidrosis
Disease Severity Scale (HDSS), a measure of self-assessed
disease severity and daily life interference in hyperhidrosis
[15]; the Dermatology Life Quality Index (DLQI) [16–18]
and the Skindex-17 [19, 20], measures of skin-related QoL.
The overall impact of hyperhidrosis on the patient was
assessed using the General Question (GQ): Over the last
7 days including today, how much has your sweating
condition affected your life? A question with similar
phrasing has been previously used in instrument validation
work in dermatology and in renal failure [17, 21]. The
burden of hyperhidrosis was also assessed in terms of daily
time spent in managing the condition, as in a previous work
in atopic dermatitis [22]. Data were also collected on socio-
demographic and disease characteristics including co-
morbidities, body site affected and treatment history.
Procedure
A web version of the new instrument was developed
and made accessible through a purposively developed web-
site for the study. The landing page of the site provided basic
study information, with additional patient-related information
(e.g. a downloadable full patient information sheet) placed
elsewhere on the site. Access to the questionnaire area
required a valid e-mail address, patient consent and a pass-
word. Consent was provided electronically. Information about
the study was posted on various online social networking
communities/sites related to hyperhidrosis.
Data processing and analysis
Data analyses in the initial construct validation step,
involving exploratory factor analysis (EFA) and Rasch
analysis, were carried out using M-PLUS 6 and
RUMM2030, respectively. In implementing the EFA,
the Weighted Least Squares (WLSMV) estimator and the
Geomin routine were used for factor estimation and for the
subsequent factor rotation [23]. The optimal number of
factors was identified using Cattel’s scree plot and Horns
parallel analysis [24]. Candidate items for removal had
their highest factor loading B0.4, a loading of 0.4–0.5 on
more than a single factor, residual variance C0.7, or poor
content match with their dominant factor [25].
In the Rasch analysis, model fit was assessed for the
entire scale, the individual items and the persons. Optimal
overall model fit is shown by mean fit residuals of 0, a
standard deviation of 1–1.5 and a non-significant
(p [ 0.05) total item–trait interaction chi-squared statistic
[26]. Fit residuals \|±2.5| indicate optimal fit for the
individual items/persons [27]. Unidimensionality and local
dependence assumptions were assessed by exploring pat-
terns in the residuals after fitting the Rasch model [28].
Differential item functioning across patient characteristics
was assessed using a two-way ANOVA test. A significant
main effect for a demographic variable indicates the pre-
sence of uniform DIF, while a significant interaction effect
(demographic variable 9 underlying impairment in QoL)
indicates the presence of non-uniform DIF [29].
Qual Life Res (2015) 24:1017–1027 1019
123
The rest of the data analysis was carried out using SPSS.
Internal consistency of scales was measured using Cron-
bach’s alpha and corrected item–total correlations. Test–
retest reliability was assessed by measuring the level of
agreement between baseline and first follow-up score using
Table 1 Socio-demographic characteristics of study participants
Cohort 1 (n = 595) Cohort 2 (n = 260)
Gender, n (%)
Male 113 (19 %) 65 (25 %)
Female 482 (81 %) 195 (75 %)
Age, years
Mean (SD) 40.5 (14.2) 37 (14)
Median 39 33
Range 18–74 17–74
Duration of condition, years
Mean (SD) 27.5 (14.1) Na.
Median 25 Na.
Range 2–69 Na.
Body are affected
Heada 129 (22 %) 24 (9 %)
Axillaa 54 (9 %) 28 (11 %)
General 130 (22 %) 56 (22 %)
Axilla, palms, feet 158 (27 %) 73 (28 %)
Palms and feet 124 (21 %) 79 (30 %)
Co-morbidityb
Menopausal
complaints
61 (10 %) 16 (6.2 %)
Diabetes 30 (5 %) 11 (4.2 %)
Hypertension 47 (8 %) 29 (11.2 %)
Neurological disorders 64 (11 %) 30 (11.5 %)
Thyroid disorders 66 (11 %) 13 (5 %)
Employment status
Employed 380 (64 %) 160 (61.5 %)
Unemployed 107 (18 %) 37 (14.2 %)
Retired 70 (12 %) 21 (8.1 %)
Full-time student 30 (6 %) 42 (16.2 %)
Country
USA 559 142 (54.6 %)
Canada 36 11 (4.2 %)
Australia Na. 11 (4.2 %)
UK Na. 73 (28.1 %)
Other countries Na. 23 (9 %)
a The classification of the body site of hyperhidrosis reflects the
predominant area of sweating
b Patients were asked to choose from a list of six conditions including
other, to complete statement ‘‘I have problems with…’’
Na not available
Table 2 Factor and structure matrix of the HidroQoL (21 items)
showing item loadings of the final 21 items fitting the exploratory
factor analysis (EFA)
Item Daily life
activities
Psychosocial
life
Residual
variance
DLA SE PS SE Variance
My physical activities are
affected
0.89 0.02 0.00 0.00 0.20
My everyday housework
is affected
0.83 0.04 -0.14 0.05 0.44
My hobbies are affected 0.63 0.04 0.13 0.05 0.48
I worry about the
additional chores in
dealing with my
condition
0.59 0.05 0.24 0.06 0.41
My holidays are affected 0.56 0.04 0.29 0.04 0.39
I worry about the
additional money in
dealing with my
condition
0.53 0.05 0.22 0.06 0.53
Sweating is constantly on
my mind
0.18 0.05 0.65 0.04 0.41
My career decisions are
affected (e.g. career
choice)
0.17 0.05 0.58 0.04 0.51
I avoid taking on new
challenges
0.13 0.04 0.76 0.03 0.29
I avoid public speaking
(e.g. presentations)
0.08 0.05 0.66 0.05 0.49
My personal relationship
are affected
0.08 0.04 0.73 0.04 0.39
I feel frustrated 0.03 0.05 0.78 0.04 0.36
I feel uncomfortable
physically expressing
affection (e.g. hugging
others)
0.02 0.05 0.77 0.04 0.39
I feel sad 0.01 0.04 0.84 0.03 0.29
I feel embarrassed 0.00 0.05 0.86 0.03 0.25
I find it hard to be near
others
0.00 0.03 0.87 0.02 0.24
I do not socialise as much
as I would like to
0.00 0.03 0.87 0.03 0.25
My self-confidence is
affected
-0.07 0.04 0.93 0.03 0.22
I feel nervous -0.08 0.04 0.90 0.03 0.28
I avoid meeting new
people
-0.12 0.04 0.93 0.03 0.25
I worry about peoples
reaction
-0.17 0.05 0.94 0.03 0.30
Factor loadings based on factor pattern matrix represent unique var-
iance in the items attributed to a particular factor
DLA daily life activities; SE standard error, PS psychosocial life
domain
The highest factor loading for each item is indicated in bold
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intra-class correlations. The relationship between the Hid-
roQoL and other measures, to establish construct validity,
was assessed using spearman’s rank-sum correlations. A
correlation of 0–0.09 is considered poor, 0.1–0.2 slight,
0.21–4 fair, 0.41–0.6 moderate, 0.61–0.8 substantial and
0.81–1 is considered perfect [30]. To assess responsive-
ness, the change in score between baseline and third
assessment was measured using a paired t test. Magnitude
of change was captured using Cohen’s effect size. The
relative precision of the new measure in detecting change
was estimated as a ratio of the t test statistics for the new
measure versus that obtained for the DLQI.
Results
Content validity
The HidroQoL was rated content valid by the expert pan-
els. The data collected allowed revision of the instrument.
The recall period was changed from ‘at present’ to ‘the last
7 days including today,’ and the option ‘not relevant’ was
removed from the response options. One item was deleted,
twenty-nine were revised, and three were added, resulting
in a 49-item developmental instrument, scored on a 5-point
Likert scale.
Construct validation and item reduction
The characteristics of the patients participating in all pha-
ses of the study are reported in Table 1. Correlation ana-
lysis (based on USA patients from cohort 1, n = 559)
showed 30 items with polychoric correlation coefficient
[0.8, suggesting multicollinearity. Following consider-
ation of content overlap and importance of the issues to
patients (based on the results of qualitative study reported
by Kamudoni et al. [13]), 13 items were removed, retaining
36 items for subsequent analyses.
Exploratory factor analysis
An exploratory factor analysis (EFA) of the HidroQoL (36
items) (based on USA patients from cohort 1, n = 559)
identified three factors. Twenty-eight items showed clear
strong loadings to a single factor, six were cross-loading on
several factors, and two had no factor loading [0.4.
Sequentially, items with poor performance were removed,
with further EFA iteratively carried out, at each step.
Subsequently, 21 items loading to two interpretable factors,
daily life activities and psychosocial life domain were
retained (Online SM 1). Two factors were to the left of the
elbow in the scree plot curve. The factor loadings ranged
from 0.53 to 0.89 and 0.58 to 0.94, respectively (Table 2).
Rasch analysis
In the Rasch analysis (based on patients from USA and
Canada from cohort 1, n = 595), the HidroQoL (36 items)
showed poor overall fit to the model (total chi-square sta-
tistic = 1,642.32, p \ 0.01), suggesting that it was not
unidimensional and that the hierarchical ordering of items
according to the underlying HRQoL varied according to its
severity. Sixteen items showed good fit (fit residuals
\|2.5|), ten items underfitted (fit residuals [2.5), and
another ten overfitted (fit residuals \2.5). Three items had
optimally functioning response option categories (33 items
had disordered category thresholds). A revision of the
response option categories from a 5-point to a 3-point scale
resolved the dysfunction (Figs. 1, 2).
Misfitting items and those showing local dependence
were sequentially removed, retaining a set of 15 items
which fulfilled strict unidimensionality requirements [the
proportion of pairs of person estimates from two subsets of
the HidroQoL items that were significantly different—
3.45 % (95 % CI 1.98, 4.92 %)] (Table 3). Six items
Fig. 1 Disordered category thresholds for the item I avoid public
speaking. Category threshold for scores 0–1 is on a higher location
(QoL impairment) than for scores 1–2. Scores 1 (= a little) and 3
(= quite a bit) have no range on the latent QoL variable over which
they are most likely
Fig. 2 Appropriately ordered category thresholds for the item I avoid
public speaking after rescoring. Following rescoring from a 5 to a 3
point scale, the category thresholds 0–1 and 1–2 are monotonically
ordered. Each score has a range on the latent QoL variable (location)
over which it is the most likely
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showed non-uniform DIF for body area, one item for dis-
ease severity, and another for co-morbidity. In four items,
the observed DIF was revealed to be compensatory rather
than real following purification process. Nonetheless, the
observed DIF had marginal impact on the performance of
the overall scale. Group-specific test characteristic curves
(TCC) were near identical for all demographic character-
istic (largest difference \0.5 logits) (Online SM 2–5).
Therefore, none of the items were removed due to DIF.
The final version of the HidroQoL
The final version of the HidroQoL adopted all items
retained in the Rasch analysis. Three additional items, my
choice of clothing is affected, I feel embarrassed and my
hobbies are affected, considered particularly important to
patients with hyperhidrosis (based on the previous quali-
tative study reported by Kamudoni et al. [13]) were
retained. The last two showed optimal fit during the EFA.
As previously noted, results from statistical models may
not always address patient priorities, raising the need for
their explicit consideration during item reduction [31]. The
final 18 items were grouped under two domains, daily life
activities domain (with 6 items) and psychosocial impact
(with 12 items), supported by the results of the EFA
(Fig. 3). The items were scored on a 3-point scale: no, not
at all = 0; a little = 1; and very much = 2.
Validation of the final HidroQoL
Reliability
The HidroQoL showed strong internal consistency (base-
line responses, cohort 2, n = 260) [Cronbach’s alpha:
overall scale, a = 0.89, daily life activities domain,
a = 0.76, psychosocial domain, a = 0.86]. The corrected
item–total correlation coefficients ranged from 0.376 to
0.618, reflecting a well-balanced scale, i.e. all items were
tapping into the underlying construct. The time between
the first (baseline) and the second (first follow-up) assess-
ment was 7 days for the majority of patients (70 %) (max -
18 days, min - 5 days). The results of the test-retest reli-
ability assessment demonstrated strong reproducibility of
the HidroQoL scores [Intra-class correlation (95 % CI):
overall scale, ICC = 0.93 (0.89, 0.95), p \ 0.001; daily
life activities, ICC = 0.88 (0.83, 0.92), p \ 0.001; psy-
chosocial impact, ICC = 0.914 (0.87, 0.94), p \ 0.001].
Similar results were observed on the individual items (ICC
range 0.792–0.876). Strong reliability was also shown in
the USA and the UK subsamples separately (Online SM 5).
These findings suggest that the HidroQoL can be reliably
used for individual-level assessment of QoL such as in
routine clinical practice.
Construct validity
All the hypotheses tested to assess construct validity of the
HidroQoL were confirmed. The HidroQoL scores corre-
lated moderately with the HDSS score [Spearman’s rank-
sum correlation (r): overall score, r = 0.59, p \ 0.001;
daily life activities, r = 0.55, p \ 0.001; psychosocial
domain, r = 0.53, p \ 0.001]. The general question (GQ)
score was positively correlated with HidroQoL scores
[overall score, r = 0.54, p \ 0.001; daily life activities,
r = 0.48, p \ 0.001; psychosocial impact, r = 0.50,
p \ 0.001]. The DLQI’s total score had a positive corre-
lation with the HidroQoL scores (overall scale, r = 0.60,
Table 3 Item fit statistics of the developmental HidroQoL (15
items) following item reduction with the Rasch model
Item Location SE FitResid chi-
square
p*
My holidays are
affected (e.g.
planning, activities)
0.51 0.085 -0.51 8.96 0.44
My hobbies are
affected
0.02 0.085 1.72 8.62 0.47
I avoid public speaking
(e.g. presentations)
0.39 0.077 1.15 16.71 0.05
My work is affected 0.54 0.085 0.74 11.44 0.25
I avoid meeting new
people
1.20 0.083 -0.31 5.62 0.78
I feel nervous -0.72 0.091 -1.99 16.91 0.05
I feel frustrated -1.03 0.095 -2.30 14.41 0.11
Sweating is constantly
on my mind
-1.05 0.096 -1.08 7.59 0.58
My appearance is
affected
-0.41 0.088 0.93 8.82 0.45
I worry about leaving
sweat marks on
things
-1.08 0.096 0.76 9.79 0.37
I worry about people’s
reactions
-2.02 0.103 -0.84 14.21 0.11
I feel uncomfortable
physically expressing
affection (e.g.
hugging others)
0.01 0.088 -1.07 9.62 0.38
My sex life is affected 1.62 0.079 0.87 11.17 0.26
I worry about the
additional chores in
dealing with my
condition
1.81 0.086 0.05 7.92 0.54
I find it hard to do
things without
planning in advance
0.22 0.083 0.54 7.85 0.55
Location indicates the relative level of QoL impairment that each
item is targeting, arranging from low (negative) to high impairment
(positive)
*p, p value; FitResid, fit residual
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The statements in this questionnaire relate to how your life has been affected by your excessive sweating 
condition (hyperhidrosis) in the last seven days including today.
Please choose one box for each statement. If a statement does not apply to you please choose ‘No, not at 
all’.
Domain 1: Daily life activities
Very much A little No, not at all
1. My choice of clothing is affected
2. My physical activities are affected
3. My hobbies are affected
4. My work is affected
5. I worry about the additional activities in dealing with my condition
6. My holidays are affected (e.g. planning, activities)
Domain 2: Psychosocial life
Very much A little No, not at all
7. I feel nervous
8. I feel embarrassed
9. I feel frustrated
10. I feel uncomfortable physically expressing affection (e.g. hugging)
11. I think about sweating
12. I worry about my future health
13. I worry about people’s reactions
14. I worry about leaving sweat marks on things
15. I avoid meeting new people
16. I avoid public speaking (e.g. presentations)
17. My appearance is affected
18. My sex life is affected
Domain 1 Score:________________ Domain 2 Score:_______________ Total score___ (out of 36) 
Please check that you have answered all questions
Thank you! 
Fig. 3 The final version of the HidroQoL with 18 items. The new hyperhidrosis-specific QoL instrument, the Hyperhidrosis Quality of Life
Index
Qual Life Res (2015) 24:1017–1027 1023
123
p \ 0.001, daily life activities domain, r = 0.52,
p \ 0.001; psychosocial impact, r = 0.56, p \ 0.001).
Finally, the HidroQoL scores correlated with the ‘amount
of time spent in managing hyperhidrosis daily’ (r = 0.42,
p \ 0.001). Further, the Skindex-17’s symptom and psy-
chosocial scales also showed slight-substantial correlations
with the HidroQoL scores [overall score, r = 0.26,
r = 0.63; daily life activities domain, r = 0.17, r = 0.48;
psychosocial impact, r = 0.28, r = 0.63]. Construct
validity was also established for the US and the UK
patients, separately (Online SM 6). The HidroQoL there-
fore is capable of measuring the key impacts of disease
central to hyperhidrosis especially those that are influenced
by the severity of the condition.
Responsiveness
Patients were grouped according to change in their disease
severity (HDSS score) from baseline to second follow-up
assessment (based on patients completing second follow-up
after 15–35 days, n = 90, cohort 2). Nineteen patients (21 %)
had minimally improved (change in HDSS score, ?1), 64
(72 %) had not changed and 6 patients (7 %) had minimally
worsened. In the minimally improving group, the mean
change scores were 1.05, 2.05 and 3.1, for the daily life
activities (p = 0.09), psychosocial domain (p = 0.003)
domains and the overall scale (p = 0.005), respectively. The
change in the overall scale score corresponded to a Cohen’s
effect sizes of 0.47 (95 % CI -0.24, 1.05). This indicates that
the HidroQoL was sensitive to change in the patient’s condi-
tion. Further, the HidroQoL score differentiated between
patients in the three groups of change [mean change, t2–t1:
minimally improved, -3.1 ± 3.85; no change, -1.58 ±
4.49; minimally worsened, 3 ± 5.25, KW-test: overall scale,
chi-squared = 6.9, p = 0.031; daily life activities domain,
chi-squared statistic = 6.8, p = 0.034; and psychosocial
domain, chi-squared = 5.9, p = 0.051)]. These results pro-
vide the evidence that the HidroQoL meets the critical
requirements for measuring QoL in a longitudinal context, the
ability to distinguish treatment responders in addition to sen-
sitivity to change.
Discussion
The impact of hyperhidrosis on the patient’s life is con-
siderable [32]. HRQoL impacts of hyperhidrosis are known
to be worse than in some skin conditions (such as psoriasis
and atopic dermatitis [33]) or (chronic illnesses such as
renal failure and diabetes [34]). The measurement of such
impacts has, until now, been a challenge, partly due to use
of inappropriate measures such as those assessing disease
severity rather than impact on the patients’ lives and a lack
of appropriately developed and validated measures of dis-
ease-specific impact. The current study describes the
development and validation of a new hyperhidrosis-specific
QoL instrument, the Hyperhidrosis Quality of Life Index
(HidroQoL).
The new instrument differs in emphasis and content
coverage from current disease-specific measures. For
example, the Hyperhidrosis Questionnaire [35] has five
domains including a domain on symptoms ‘physical
domain.’ Similarly, in the Hyperhidrosis Quality of Life
questionnaire [36], one of its four domains seems to rep-
resent severity rather than impacts of disease. Symptom
and severity-related items are not included in the new
instrument (the HidroQoL), as these were demonstrated by
factor analysis and Rasch analysis to lie outside the domain
of QoL impact of hyperhidrosis. Further, impacts on self-
image and embarrassment not included in the Hyperhi-
drosis Impact Questionnaire [37] are covered in the
HidroQoL.
An online social networking patient population repre-
sents a number of advantages for the HidroQoL. The
measure’s content reflects the experiences of patients often
excluded from PRO development, the non-clinic patients.
In hyperhidrosis, this group makes up 65 % of all patients
[3]. The participation of patients from multiple countries in
the study enhanced the universality of the new measure.
Furthermore, the involvement of patients as experts, eval-
uating the quality and relevance of the HidroQoL’s con-
tent, during the content validations step, contributed to the
patient-centredness of the HidroQoL. On matters of item
relevance, the views of the patient panel carried more
weight as they were reporting based on first-hand experi-
ence. Input from the patient and clinician experts provided
useful insights facilitating the revision of the measure.
The initial construct validation and item reduction were
based on a large and heterogeneous patient population
reflecting all forms of hyperhidrosis and different levels of
disease severity. Use of techniques from modern test theory
during this step means that the HidroQoL reflects the
highest measurement standards and precision, e.g. invari-
ance of items across various demographic groups. The item
reduction based on exploratory factor analysis and Rasch
analysis resulted in slightly different item selection, with
11 common items. The factor analysis–Rasch analysis
friction can be traced to the lack of a ‘linear ruler’ (con-
tinuum) on which the items are ordered according to the
level of impairment in the underlying QoL construct they
refer to, within EFA [38]. Further, local dependence
(influence of responses of one item on another) is explicitly
addressed in the Rasch model. Nonetheless, the EFA was
useful in identifying the domains of the measure. The
HidroQoL’s item scores can be summed to form sub- and
overall scale scores: Q1–Q6 as the daily life activities
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domain score, items Q7–Q18 as the psychosocial impact
domain score and all items as overall scale score. The
individual items are assumed to have equal weighting,
supporting a simple arithmetic summation in the calcula-
tion of domain and overall score. This is underpinned by
properties of the Rasch model: (1) item responses are
determined by the difference between the location of an
item on the latent variable (i.e. level of QOL impairment
being targeted by an item) and the location of the person on
the same variable (i.e. level of QOL impairment of a per-
son) [39]; (2) items are assumed to have equal ability to
discriminate (slope parameter), while targeting different
levels of the latent variable [40].
As item reduction based on statistical models depends
on the pattern of responses or correlations among items, the
preferences/priorities of the patient are not directly taken
into account. This poses a risk to the content validity of a
measure, if items core to the construct under assessment
demonstrate poor fit and are consequently removed.
Therefore, it is essential to make qualitative considerations
when making final decisions related to item revision. To
resolve this tension, for the HidroQoL, three items were
retained to preserve the integrity of the construct (these
emerged as the most prevalent themes during the qualita-
tive interviews preceding the current work) [13].
The study design considered an interval of 7 days for the
first follow-up assessment (to test reproducibility). Seven
days are considered appropriate interval between assessment
points (test 1 and 2) for such a psychometric property, as it is
not too long for the patient’s condition to have changed and
not too short to risk patients remembering responses to a
previous assessment [41, 42] to avoid underestimation and
overestimation. The planned duration of the second follow-
up of 21 days for the assessment of responsiveness was
based on expected time to euhidrosis following non-surgical
treatment (excluding Botox), such as Aluminium Chloride
(1–3 weeks) and Iontophoresis (1–4 weeks) [4]. During data
collection, some patients responded to their first and second
follow-up assessments earlier or later that instructed. Their
observations were still included in the analysis.
The HidroQoL may be applied in routine clinical prac-
tice in various ways. First, scores for the different indi-
vidual items might alert the clinicians regarding the area
the patient might be experiencing the most problems,
facilitating discussion between patient and clinicians dur-
ing consultation [43]. Where necessary, the clinician may
be able to refer the patient for psychiatric services, coun-
selling or other services, based on results of the HidroQoL.
Second, the strong association of the HidroQoL scores with
patient’s disease severity (HDSS scores) suggests that the
HidroQoL might also be useful in the diagnosis of hyper-
hidrosis [4]. For example, a score above a given cut-off
value (to be determined in future studies) might be
indicative of significant HRQoL impacts, which may serve
as confirmation of a hyperhidrosis diagnosis, in addition
to fulfilment of clinical criteria. This is particularly
important considering the role the assessment of daily
life impacts plays in the diagnosis and clinical manage-
ment of hyperhidrosis [4].
Further, the established responsiveness and test–retest
reliability of the measure means that the HidroQoL may be
used for monitoring treatment response for patients. It is
important to bear in mind that the currently presented
psychometric properties are based on the online version of
the HidroQoL. As this version was designed with minimal
alterations to the paper and pencil version (e.g. use of radial
buttons as opposed to check boxes for responses), a full
validation study may not be necessary to confirm the
observed psychometric attributes for the paper and pencil
version of the HidroQoL (see Coons et al. [44]).
This study faced a number of limitations. First, not all
patients from baseline assessment completed the consecu-
tive follow-up assessments. It was not possible to ascertain
the reasons for non-response, given the study design.
Second, as the data collection was undertaken electroni-
cally with no clinic visits, there was no clinical confirma-
tion of the participant’s diagnosis as hyperhidrosis. An idea
during the design phases of the study was to request
patients for records that would demonstrate their hyperhi-
drosis-diagnosis such as a prescription receipt. This was,
however, not implemented considering the potential burden
on the patients. Nonetheless, 85 % of patients self-reported
seeing a clinician for the condition.
Further, online social networking patient populations
may be associated with some self-selection bias. A previ-
ous study reported greater dissatisfaction with treatment
and less self-rated therapeutic benefit in an online psoriatic
patient population relative to a clinic population [45]. In
addition, patients’ membership to online social networking
communities presumes computer literacy and internet
access, automatically excluding those without.
Nevertheless, a number of considerations exonerate the
above concerns. First, it could be argued that the study
sample is more representative of the hyperhidrosis patient
population at large because it included both clinic and non-
clinic patients. The current levels of internet usage (UK,
82 %; USA, 77.2 %) [46], also, suggest that those without
access might actually be in the minority. Furthermore,
whereas there might be practical and logistical challenges
with obtaining sufficient patient numbers in local clinics
(due to the prevalence of hyperhidrosis—2.8 %, the
majority of whom do not seek for medical attention [3]),
online patient support communities offer an alternative
source of research participants, without geographical lim-
itations. Pertinently, the current sample showed heteroge-
neity across important disease characteristics.
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The current research sets a new standard for the mea-
surement of HRQoL in hyperhidrosis. A ‘third-generation’
disease-specific QoL instrument for hyperhidrosis, rooted
in the experiences of patients and validated in a large
international sample based on modern test theory, is now
available. The perennial nature of instrument validation
means that there is still further work to be carried out on
the new instrument. A study to identify minimal clinically
important difference (MCID) and scale banding system for
the HidroQoL scores has been planned. Even more
importantly, the psychometric properties demonstrated by
the HidroQoL will need to be confirmed in patients in
clinic settings.
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